35. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 27 or the pharmaceutical composition of claim 34 for use as a medicament.

36. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 27 or the pharmaceutical composition of claim 34 for use in the treatment of a disease in an individual in need thereof.

37. The T cell activating bispecific antigen binding molecule or the pharmaceutical composition of claim 36, wherein the disease is cancer.

38. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 27 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

39. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 27 in a pharmaceutically acceptable form.

40. The use of claim 38 or the method of claim 39, wherein said disease is cancer.

41. A method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1-27 in the presence of a T cell.

~~42. The invention as described hereinbefore.~~